0	12	Reactivation	Reactivation	NNP
13	15	of	of	IN
16	22	Kaposi	Kaposi	NNP
22	24	’s	's	POS
25	43	sarcoma-associated	sarcoma-associated	JJ
44	55	herpesvirus	herpesvirus	NN
56	65	infection	infection	NN
66	70	from	from	IN
71	78	latency	latency	NN
79	81	by	by	IN
82	92	expression	expression	NN
93	95	of	of	IN
96	99	the	the	DT
100	103	ORF	ORF	NNP
104	106	50	50	CD
107	121	transactivator	transactivator	NN
121	122	,	,	,
123	124	a	a	DT
125	132	homolog	homolog	NN
133	135	of	of	IN
136	139	the	the	DT
140	143	EBV	EBV	NNP
144	145	R	r	NN
146	153	protein	protein	NN
153	154	.	.	.

156	162	Kaposi	Kaposi	NNP
162	164	’s	's	POS
165	172	sarcoma	sarcoma	NN
173	174	(	(	(
174	188	KS)-associated	ks)-associated	JJ
189	200	herpesvirus	herpesvirus	NN
201	202	(	(	(
202	206	KSHV	KSHV	NNP
206	207	)	)	)
207	208	,	,	,
209	211	or	or	CC
212	217	human	human	JJ
218	229	herpesvirus	herpesvirus	NN
230	231	8	8	CD
231	232	,	,	,
233	235	is	be	VBZ
236	237	a	a	DT
238	250	lymphotropic	lymphotropic	JJ
251	256	virus	virus	NN
257	265	strongly	strongly	RB
266	272	linked	link	VBN
273	275	to	to	TO
276	283	several	several	JJ
284	296	AIDS-related	aids-related	JJ
297	306	neoplasms	neoplasm	NNS
306	307	.	.	.

308	311	The	the	DT
312	319	primary	primary	JJ
320	329	reservoir	reservoir	NN
330	332	of	of	IN
333	342	infection	infection	NN
343	351	consists	consist	VBZ
352	354	of	of	IN
355	363	latently	latently	RB
364	372	infected	infected	JJ
373	374	B	B	NNP
375	386	lymphocytes	lymphocyte	NNS
387	390	and	and	CC
391	399	possibly	possibly	RB
400	405	other	other	JJ
406	417	mononuclear	mononuclear	JJ
418	423	cells	cell	NNS
423	424	.	.	.

425	430	Viral	viral	JJ
431	443	reactivation	reactivation	NN
444	448	from	from	IN
449	456	latency	latency	NN
457	460	and	and	CC
461	467	spread	spread	NN
468	472	from	from	IN
473	477	this	this	DT
478	486	lymphoid	lymphoid	JJ
487	496	reservoir	reservoir	NN
497	499	is	be	VBZ
500	510	presumably	presumably	RB
511	519	required	require	VBN
520	523	for	for	IN
524	535	development	development	NN
536	538	of	of	IN
539	550	nonlymphoid	nonlymphoid	JJ
551	557	tumors	tumor	NNS
558	562	like	like	IN
563	565	KS	ks	NN
565	566	.	.	.

567	571	Here	here	RB
572	574	we	we	PRP
575	579	show	show	VBP
580	584	that	that	IN
585	596	deregulated	deregulate	VBN
597	607	expression	expression	NN
608	610	of	of	IN
611	612	a	a	DT
613	619	single	single	JJ
620	625	viral	viral	JJ
626	630	gene	gene	NN
630	631	,	,	,
632	635	ORF	ORF	NNP
636	638	50	50	CD
638	639	,	,	,
640	645	which	which	WDT
646	653	encodes	encode	VBZ
654	655	a	a	DT
656	670	transactivator	transactivator	NN
671	675	able	able	JJ
676	678	to	to	TO
679	690	selectively	selectively	RB
691	701	upregulate	upregulate	VB
702	715	delayed-early	delayed-early	JJ
716	721	viral	viral	JJ
722	727	genes	gene	NNS
727	728	,	,	,
729	737	suffices	suffice	NNS
738	740	to	to	TO
741	748	disrupt	disrupt	VB
749	756	latency	latency	NN
757	760	and	and	CC
761	767	induce	induce	VB
768	771	the	the	DT
772	777	lytic	lytic	JJ
778	782	gene	gene	NN
783	790	cascade	cascade	NN
791	793	in	in	IN
794	802	latently	latently	RB
803	811	infected	infected	JJ
812	813	B	B	NNP
814	819	cells	cell	NNS
819	820	.	.	.

821	824	The	the	DT
825	839	identification	identification	NN
840	842	of	of	IN
843	847	this	this	DT
848	852	gene	gene	NN
853	858	opens	open	VBZ
859	862	the	the	DT
863	866	way	way	NN
867	869	to	to	TO
870	877	studies	study	NNS
878	880	of	of	IN
881	884	the	the	DT
885	896	physiologic	physiologic	JJ
897	907	mechanisms	mechanism	NNS
908	919	controlling	control	VBG
920	931	reactvation	reactvation	NN
932	934	of	of	IN
935	939	KSHV	KSHV	NNP
940	944	from	from	IN
945	952	latency	latency	NN
952	953	.	.	.

954	963	Copyright	Copyright	NNP
964	968	1998	1998	CD
969	977	Academic	Academic	NNP
978	983	Press	Press	NNP
983	984	.	.	.